GHENT, BELGIUM--(Marketwire - September 12, 2012) - Ablynx [Euronext Brussels: ABLX] announces
that it will be presenting at the UBS Global Life Sciences Conference,
taking place from 19-20 September at the Grand Hyatt, New York.
The presentation, followed by a Q&A, will be hosted by Dr Edwin Moses,
Chairman of Ablynx on Thursday, 20 September at 02:00 p.m. EST / 08:00 p.m.
A live webcast of the event will be available via the following link.
Users are recommended to register at least 10 minutes ahead of the
Shortly after the presentation, a replay of the webcast will be available
Company's website www.ablynx.com.
Ablynx is a biopharmaceutical company engaged in the discovery and
of Nanobodies®, a novel class of therapeutic proteins based on
antibody fragments, for a range of serious human diseases,
inflammation, haematology, oncology and pulmonary disease. Today, the
has approximately 25 programmes in the pipeline and seven Nanobodies
clinical development stage. Ablynx has ongoing research
significant partnerships with major pharmaceutical companies,
Boehringer Ingelheim, Merck Serono and Novartis. The Company is
Ghent, Belgium. More information can be found on www.ablynx.com.
pdf version of the press release:
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Ablynx via Thomson Reuters ONE